Sanggenone C
Sanggenone C inhibits tumor cellular proteasomal activity and cell viability, via induction of cell cycle arrest and cell death , inhibiting the proteasome function. It inhibited NO production and iNOS expression by suppressing NF-κB activity and IκBα activation; inhibited TNF-alpha -stimulated PMN-HSC adhesion and expression of VCAM-1 by suppressing the activation of NF-kappaB.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Nutr Res Pract.2020, 14(3):203-217.
Sci Rep.2018, 8:9267
Appl. Sci.2022, 12(17), 8646.
Appl. Sci.2020, 10(20),7374.
Eur J Pharm Sci.2016, 94:33-45
J Pharm Biomed Anal.2019, 172:268-277
An Acad Bras Cienc.2023, 95(3):e20220672
Front Pharmacol.2019, 10:1226
Proc Natl Acad Sci USA.2016, 113(30):E4407-1
Braz J Biol.2023, 82:e266573.
Related and Featured Products
Immunopharmacol Immunotoxicol. 2012 Feb;34(1):84-8.
Sanggenon C and O inhibit NO production, iNOS expression and NF-κB activation in LPS-induced RAW264.7 cells.[Pubmed:
21612567]
Sanggenone C and O, two Diels-Alder type adducts isolated from Morus alba, a plant has been used for the anti-inflammatory purpose in the Oriental medicine, were investigated for their effect on the NO production, iNOS expression and NF-κB activity.
METHODS AND RESULTS:
The inhibitory effects of Sanggenone C and O on the NF-κB activity were investigated in LPS-stimulated RAW264.7 cells by SEAP reporter assay.Sanggenon O showed stronger inhibition than the diastereomer Sanggenone C. Both compounds prevented the phosphorylation and degradation of IκBα protein.
CONCLUSIONS:
We demonstrated that Sanggenone C and O inhibited NO production and iNOS expression by suppressing NF-κB activity and IκBα activation.
Acta Pharmacol Sin. 2002 Feb;23(2):138-42.
Inhibitory effect and mechanism of action of sanggenon C on human polymorphonuclear leukocyte adhesion to human synovial cells.[Pubmed:
11866874]
To examine the effect of Sanggenone C on human polymorphonuclear leukocyte (PMN) adhesion to human synovial cell(HSC), and explore its mechanism.
METHODS AND RESULTS:
Adhesion of PMN to HSC was measured by MTT colorimetry. Cell-ELISA and RT-PCR methods were used to examine the expression of adhesion molecules ICAM-1 and VCAM-1. Activation of nuclear factor-kappa B(NF-kappaB) was measured by electrophoretic mobility shift assays(EMSA) method. Sanggenone C effectively inhibited TNF-alpha (50 kU/L for 12 h) and IL-1beta (50 kU/L for 12 h) induced adhesion of PMN to HSC (IC50 27.29 nmol/L and 54.45 nmol/L, respectively) in a concentration-dependent manner. Adhesion molecule VCAM-1 surface protein and mRNA expression induced by TNF-alpha 50 kU/L were significantly inhibited by Sanggenone C, nevertheless, for ICAM-1 only surface protein expression being inhibited. The activation of NF-kappaB was also extensively inhibited by Sanggenone C.
CONCLUSIONS:
Sanggenone C inhibited TNF-alpha -stimulated PMN-HSC adhesion and expression of VCAM-1 by suppressing the activation of NF-kappaB.
Front Biosci (Elite Ed). 2011 Jun 1;3:1315-25.
Sanggenon C decreases tumor cell viability associated with proteasome inhibition.[Pubmed:
21622138]
We report for the first time that Sanggenone C, a natural prenylated flavonoid, inhibits tumor cellular proteasomal activity and cell viability.
METHODS AND RESULTS:
We found that (1) Sanggenone C inhibited tumor cell viability and induced cell cycle arrest at G0/G1 phase; (2) Sanggenone C inhibited the chymotrypsin-like activity of purified human 20S proteasome and 26S proteasome in H22 cell lysate, and Sanggenone C was able to dose-dependently accumulate ubiquitinated proteins and proteasome substrate protein p27; (3) Sanggenone C-induced proteasome inhibition occurred prior to cell death in murine H22 and P388 cell lines; (4) Sanggenone C induced death of human K562 cancer cells and primary cells isolated from leukemic patients.
CONCLUSIONS:
We conclude that Sanggenone C inhibits tumor cell viability via induction of cell cycle arrest and cell death, which is associated with its ability to inhibit the proteasome function and that proteasome inhibition by Sanggenone C at least partially contributes to the observed tumor cell growth-inhibitory activity.
Zhong Yao Cai. 2013 Apr;36(4):553-7.
[Study on quality standard for mori cortex].[Pubmed:
24133999]
METHODS AND RESULTS:
UV was used for determination the centent of total flavonoids of Mori Cortex with Sanggenone C as the reference substance. HPLC was applied for determination the contents of sanggenons C, D and DNJ of Mori Cortex. In the TLC chromatogram, sanggenon D showed a distinct fluorescence spot under UV 365 nm with good separation. In UV, Sanggenone C calibration curve showed a good linear relationship at the range of 146.8 - 734.0 microg/mL, the average recovery was 97.4% (RSD = 2.1%); For the HPLC quantitation method, Sanggenone C, sanggenone D and DNJ showed good linear within the scope of 700 - 4 000 microg, 500 - 3 000 microg and 4.8 - 96 microg, respectively.
CONCLUSIONS:
The average recovery of Sanggenone C, sanggenone D and DNJ were 98.8% (RSD = 2.6%), 99.1% (RSD = 2.2%) and 98.9% (RSD = 1.7%), respectively.
